Synta Pharmaceuticals slides after Q3 results

Shares of Synta Pharmaceuticals (SNTA -6.3%) are notably lower on the session.

Highlights from the company's Q3 report include: Final OS results from GALAXY-1 by "early 2014;" interim and final analyses of GALAXY-2 in H2 2014 and H1 2015, respectively; ENCHANT-1 initial results at the San Antonio Breast Cancer Symposium in December; cash position at quarter's end was $53.4M (versus $100.6M as of December 31, 2012), enough to last "into Q2 2014." (PR)

According to market chatter, Roth Capital thinks the company could have a partnership "up its sleeve."

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs